Global Angiotensin Receptor Blockers ARBs Market Size By Type (Valsartan, Telmisartan), By Application (Hypertension, Cardiovascular Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Angiotensin Receptor Blockers (ARBs) Market was valued at USD 9.1 billion in 2023 and is expected to surpass USD 15.4 billion by 2031, growing at a CAGR of 6.7% during the forecast period (2023–2031). This growth is driven by the rising prevalence of hypertension and cardiovascular diseases, increasing geriatric population, and the expanding awareness about the benefits of ARBs as first-line therapy in hypertension management. ARBs are widely prescribed due to their tolerability and ability to lower blood pressure without significant side effects, further enhancing their adoption.

Drivers:

1. Rising Prevalence of Hypertension and Cardiovascular Diseases:

The increasing global burden of hypertension, especially in low- and middle-income countries, is a major growth driver. ARBs play a critical role in blood pressure management and in reducing the risk of stroke and heart failure.

2. Aging Population:

The aging demographic is more prone to chronic diseases like hypertension and kidney dysfunction, which require long-term ARB therapy, thus boosting market growth.

3. Favorable Drug Profile and Physician Preference:

ARBs are preferred for their high efficacy, minimal side effects, and renal-protective benefits. Their increasing prescription as monotherapy or in combination treatments is driving demand.

Restraints:

1. Generic Drug Competition:

Several ARBs have lost patent protection, leading to the proliferation of low-cost generics. This puts pricing pressure on branded products and restrains revenue growth for leading pharmaceutical companies.

2. Regulatory and Safety Concerns:

Stringent regulatory scrutiny and past recalls related to contamination issues in ARBs such as valsartan have led to heightened caution and impacted consumer confidence.

Opportunity:

1. Innovation in Fixed-Dose Combinations (FDCs):

R&D in combining ARBs with other antihypertensives (like calcium channel blockers or diuretics) in single-pill combinations is expected to offer lucrative growth opportunities, improving adherence and clinical outcomes.

2. Market Penetration in Emerging Economies:

Rapid urbanization, increasing lifestyle-related diseases, and improved healthcare access in Asia-Pacific and Latin America are expected to accelerate ARB adoption in these high-potential markets.

Market by System Type Insights:

Based on system type, the Valsartan segment accounted for the largest market share in 2023 due to its widespread usage and clinical efficacy. However, the Azilsartan segment is anticipated to witness the fastest growth due to its improved pharmacodynamic properties and newer approval status, driving higher adoption in developed markets.

Market by End-use Insights:

By end-use, the Hospitals & Clinics segment dominated in 2023, holding over 55% of the market share, driven by the large-scale diagnosis and treatment of hypertension through institutional prescriptions. The Retail Pharmacies segment is expected to grow rapidly, supported by patient preference for easy access to generics and over-the-counter availability in some regions.

Market by Regional Insights:

North America led the ARBs market in 2023, owing to the high prevalence of hypertension, robust healthcare infrastructure, and presence of key market players. However, Asia-Pacific is projected to register the fastest CAGR during the forecast period due to increasing health awareness, rising disposable incomes, and government initiatives to combat non-communicable diseases.

Competitive Scenario:

Key players in the global ARBs market include Novartis AG, Pfizer Inc., Merck & Co., Inc., Daiichi Sankyo Company, Ltd., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sanofi S.A., and Lupin Limited. These companies are focusing on product development, strategic collaborations, and expanding geographic reach to strengthen their competitive positioning.

Key Market Developments:

2023: Daiichi Sankyo launched an enhanced formulation of Olmesartan with improved bioavailability in the Japanese market.

2024: Novartis announced new clinical trial results showing long-term renal protection benefits of Valsartan-based combinations.

2025: Lupin Limited expanded its ARB portfolio across Latin America through new distribution partnerships.

Scope of Work – Global Angiotensin Receptor Blockers (ARBs) Market

FAQs:

1) What is the current market size of the Global Angiotensin Receptor Blockers (ARBs) Market?

The market was valued at USD 9.1 billion in 2023.

2) What is the major growth driver of the Global Angiotensin Receptor Blockers (ARBs) Market?

The primary growth driver is the rising prevalence of hypertension and cardiovascular diseases worldwide.

3) Which is the largest region during the forecast period in the Global Angiotensin Receptor Blockers (ARBs) Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in the Global Angiotensin Receptor Blockers (ARBs) Market?

The Valsartan segment led the market by system type in 2023.

5) Who are the key market players in the Global Angiotensin Receptor Blockers (ARBs) Market?

Key players include Novartis AG, Pfizer Inc., Daiichi Sankyo Company, Merck & Co., Teva Pharmaceuticals, and Lupin Limited.